Introduction
Interactions of cells with components of the extracellular matrix are important for cellular processes like migration, adhesion, proliferation and signal transduction. Hyaluronic acid (HA) is an abundant component of the extracellular matrix. Three receptors for HA on the cell surface, namely CD44 (Aruo et al., 1990) , RHAMM (Turley et al., 1987) and LYVE (Banerji et al., 1999) , have been identi®ed. CD44, the principal cellular surface receptor for hyaluronic acid, comprises a family of many isoforms (85 ± 200 kDa) that arise through alternative splicing of the preRNA and dierent degrees of glycosylation (Naor et al., 1997) . CD44s, the standard isoform of the molecule lacking variant epitopes (85 ± 90 kDa) is widely expressed in dierent tissues and cell types. In addition, CD44 expression is enhanced in a variety of malignant tumors (Naor et al., 1997) .
The standard isoform of CD44 binds strongly to hyaluronic acid and amino acid substitutions in the N-terminal part of CD44 led to the characterization of residues which are critical for HA binding (Bajorath et al., 1998; Liao et al., 1995; Peach et al., 1993; Yang et al., 1994) . Ligand binding of CD44 has been associated with many cellular processes such as migration, adhesion, signaling and proliferation (Naor et al., 1997) . In human melanoma the in¯uence of hyaluronic acid on cell migration has been shown to be CD44 dependent (Thomas et al., 1992) and increased synthesis of hyaluronic acid by melanoma cells is associated with enhanced motility of the cells (Ichikawa et al., 1999) . The capacity of HA to induce cell proliferation has been demonstrated by a number of investigators (Greco et al., 1998; West and Kumar, 1989) . Evidence for direct CD44-HA interactions resulting in HA stimulated cell proliferation has been provided for eosinophils (Hamann et al., 1995) , B-cells (Ra® et al., 1997) , T-cells (Galandrini et al., 1994) and keratinocytes (Kaya et al., 1997) . For human melanoma cells, HA-induced cell proliferation is completely dependent on CD44-HA interactions (Ahrens et al., 2001) .
Modulation of hyaluronic acid synthesis and accumulation around tumor cells has been implicated as playing a critical role in tumor development and metastasis Ropponen et al., 1998; Victor et al., 1999; Zhang et al., 1995) . In several cases, tumor progression and metastasis formation is mediated by interactions between hyaluronic acid and cell surface CD44 (Peterson et al., 2000; Sy et al., 1991 Sy et al., , 1992 Yu et al., 1997) . Also for human melanoma, interactions of surface CD44 and hyaluronic acid have been postulated to promote melanoma growth (Bartolazzi et al., 1994) .
Proteolytic cleavage of CD44 from the cell surface has been observed in dierent cell types (Bazil and Horejsi, 1992; Friedl et al., 1997; Goebeler et al., 1996; Gunthert et al., 1996; Okamoto et al., 1999) . Increased levels of soluble CD44s and soluble CD44v in the circulation of cancer patients have also been discussed as prognostic markers of disease progression. A correlation of high serum levels of CD44s with tumor burden and metastasis was found in patients with gastric or colon cancer (Guo et al., 1994) . High serum levels of soluble CD44 compared to healthy donors were found in patients with ovarian cancer (Zeimet et al., 1997) . After subcutaneous transplantation of mammary carcinomas, levels of shedded human CD44 in the serum of mice correlated with tumor size (Fichtner et al., 1997) . In the case of melanoma, serum levels of solCD44s and solCD44v were not signi®cantly elevated, although increased levels of solCD44s were detected in the serum of some patients with primary and metastatic malignant melanoma (Schaider et al., 1997) .
The physiological consequences of CD44 shedding and a possible function of the cleaved soluble CD44 protein are not completely understood to date. Migration of a highly metastatic melanoma cell line on immobilized hyaluronic acid was associated with increased CD44s turnover and shedding of the molecule (Goebeler et al., 1996) . Shedding of CD44 was also observed in malignant melanoma cells migrating in a 3D-Collagen-Matrix (Friedl et al., 1997) , but in a mixed hyaluronic acid-collagen matrix rather integrins than CD44 are the mediators of MM cell migration (Maaser et al., 1999) . Finally, a protease inhibitor was able to block the CD44-dependent migration of a lung cancer cell line on a HA coated substrate, indicating a possible role of CD44 shedding during cell migration (Okamoto et al., 1999) .
Possible functions of soluble CD44 have also been investigated using recombinant CD44s-Rg fusion proteins. Constant application of a CD44s-Rg fusion protein was able to suppress tumor growth of subcutaneously injected tumor cells in nude mice (Bartolazzi et al., 1994; Sy et al., 1992) . Application of a CD44v10-Rg fusion protein prevented metastasis formation in a mouse model, extending possible tumor suppressive functions to epitope v10-containing isoforms of CD44 (Zawadzki et al., 1998) . Using another approach, secreted soluble CD44v6-v10 was able to suppress tumor growth of murine mammary carcinoma cells and metastasis formation in vivo (Peterson et al., 2000; Yu et al., 1997) . Increased apoptosis of soluble CD44-secreting tumor cells was observed, perhaps caused by interference of soluble CD44 with cell surface CD44-hyaluronic acid interactions (Yu et al., 1997) .
In this paper we address the physiological consequences of soluble CD44s release on human melanoma tumor growth in vivo and on the proliferative capacity of human MM cells in vitro. We demonstrate that competition of cell surface CD44 and soluble CD44 for HA binding sites interferes with HAdependent processes in these cell lines, suggesting a possible function for soluble CD44. Additionally, we provide evidence for the mechanism underlying CD44 shedding in melanoma cell lines by using protease inhibitors.
Results

Shedding of CD44 in MM cell lines
To investigate the extent to which CD44 is shed from the surface of melanoma cells and whether this has any impact on tumor cell function, we ®rst tested a number of dierent melanoma cell lines in vitro for their ability S-Methionine/ Cysteine. CD44 in total cell lysates (Ly) and cell culture supernatants (SN) was immunoprecipitated with the antipanCD44 mAb Hermes 3 (5 mg/ml) and Protein A/G Sepharose (Ly+aCD44; SN+aCD44). As a control, unspeci®c binding of proteins to Protein A/G Sepharose was included (Ly Ctrl; SN Ctrl). Immunoprecipitated proteins were separated by SDS ± PAGE, gels were dried and analysed by autoradiography solCD44-HA interactions and MM tumor progression T Ahrens et al to shed CD44 from the cell surface into the cell culture supernatant (Figure 1 ). Immunoprecipitation of CD44 from radioactively labeled cells was performed to identify CD44 in the protein lysate and the cell culture supernatants. High levels of released CD44 were detected in supernatants of the cell lines MV3 and HT144 (Figure 1 ; SN+aCD44), low levels of soluble CD44 were detected in the MM cell lines SB1 and SB3, whereas no soluble CD44 was found in the supernatants of the cell line 1F6 and a primary melanocyte preparation (Figure 1 ; Mel P2). The apparent molecular weight of the shedded CD44 is 70 kDa, most likely re¯ecting the truncated form of the 85 kDa membrane-bound CD44s molecule (Figure 1 ; Ly+aCD44). Antibodies speci®c for the variant epitopes CD44v4, CD44v6 and CD44v9 were unable to immunoprecipitate variant CD44 isoforms out of cell lysates and cell culture supernatants (data not shown). We conclude that soluble CD44 from the malignant melanoma cells tested does not contain signi®cant amounts of variant CD44 epitopes and represents the truncated standard part of the molecule lacking the transmembrane and the cytoplasmic domain.
Metalloprotease and serine protease inhibitors completely prevent shedding of CD44 in MM cells
Little is known about the cleavage site of the CD44 protein and the responsible protease. In an attempt to specify proteases involved in CD44 cleavage from the cell surface of MM cells, we performed protease inhibitor studies with the cell lines MV3 and HT144, which shed CD44 (Figure 2 ). MV3 and HT144 cells were cultured for 6 h and levels of shedded soluble CD44 in the culture supernatant were measured as controls (Figure 2a,b ; Medium-Ctrl 6 h). At this time point dierent protease inhibitors were added for an additional 6 h period. Culture supernatants were then collected again and solCD44 levels were determined using a CD44-ELISA. The eects of protease inhibitors on CD44 shedding were analysed in comparison to solCD44 levels in 12 h culture media from non-treated cells (Figure 2a ,b; Medium-Ctrl 12 h). Addition of 2 mM of the metalloprotease inhibitor 1,10-Phenanthroline resulted in a 100% inhibition of CD44 shedding for both MM cell lines. The serine protease inhibitor AEBSF (2 mM) also eciently blocked the proteolytic cleavage of CD44 in these two MM cell lines (Figure 2a,b) . All other tested protease inhibitors, among them Pepstatin A and Phosphoramidon, showed only minor eects on CD44 shedding. Toxic eects of protease inhibitors on cell viability or eects on protein synthesis in general are often observed in this type of experiment. The kinetics of inhibition of cell surface shedding of CD44 within 6 h compared to the half-life of CD44 on the cell surface which is in the range of 12 ± 20 h (Goebeler et al., 1996; Gunthert et al., 1996) strongly argues for an active process of shedding and inhibition than for an eect of the inhibitors at the level of protein synthesis. To test for possible cytotoxic eects of these protease inhibitors we analysed cell viability by measuring LDH-release into the culture medium which is indicative of membrane disruption in dying cells (Figure 2c,d ). The addition of 1,10-Phenanthroline and AEBSF did not exert toxic eects on MV3 and HT144 cells when compared to non-treated cells (Figure 2c,d ; Medium-Ctrl). Phosphoramidon and Pepstatin were also found to be non toxic for the MM cells. LDH concentrations measured in the cytosol of MM cells in contrast reached 250 U/L (data not shown). In conclusion, metalloproteases and serine proteases are the main mediators of cell surface cleavage of CD44 in MM cells.
Generation of soluble CD44s expressing transfectants of the MM cell line 1F6
A function of native soluble CD44s and its impact on cellular processes like adhesion and proliferation has not been analysed in detail for human malignant melanoma. To investigate the function of soluble CD44 in a de®ned cell system, the cell line 1F6 which does not shed CD44 was stably transfected with cDNAs encoding truncated forms of CD44s. The CD44 cDNA used for transfection encodes the standard CD44 exons 1 ± 5, 15 and 16 (Figure 3a ; solCD44s), excluding the variant exons v2-10 ( Figure 3a ; hu CD44-Gene). A TGA translation stop-codon was added to the 3' end of the coding sequence of exon 16 resulting in secretion of solCD44s which is devoid of the transmembrane (exon 17) and the cytoplasmic domain (exon 18 or 19).
The cDNA encoding the soluble form of CD44s was point mutated in the codon for amino acid 41, which has been shown to be critical for the HA binding function of CD44 (Peach et al., 1993) . This mutation results in an amino acid substitution of arginine 41 to alanine in solCD44s (Figure 3a ; solCD44sR41A). Important residues for the HA binding function of CD44 are also arginine 150 and arginine 154 (Liao et al., 1995; Peach et al., 1993) . The codons for these two amino acids were also subjected to site directed mutagenesis, resulting in arginine to alanine substitutions ( Figure 3a ; solCD44sR150A/R154A).
After transfection individual cell clones were analysed for expression of the secreted proteins by CD44-ELISA ( Figure 3b ). Non-transfected, control-transfected and transfected melanoma cells were cultivated for 48 h, then medium was removed and analysed for soluble CD44 content. Transfection of cDNAs encoding wild type or mutated solCD44s resulted in the release of 125 ± 300 ng CD44 per ml culture medium ( Figure 3b ). This was equal to the amounts shedded by the non-transfected melanoma cell lines MV3 and HT144. In the culture medium of the parental cell line 1F6 and control-transfectants ( Figure 3b ; 1F6 pcDNA3-Ctrl) almost no soluble CD44 was detected.
Two hundred and ®fty ng soluble CD44 of the dierent transfectants were analysed by Western blotting to estimate the apparent molecular weights of the secreted proteins (Figure 3c ). Soluble CD44s released by the transfected cells ( Figure 3c ; lanes 2 ± 4) migrated with an apparent molecular weight of 75 kDa which is slightly higher than the naturally cleaved form shown to be approximately a 70 kDa protein ( Figure  1 ). No soluble CD44 was detected in the supernatant of non transfected 1F6 cells (Figure 3c ; lane 1).
MM cell adhesion to hyaluronic acid is inhibited by solCD44s
The solCD44s-expressing cell lines were ®rst analysed for surface expression of CD44 and basal proliferation. No signi®cant dierences compared to the nontransfected or control-transfected cells were observed (data not shown). To test for competition of soluble CD44s and cell surface CD44 regarding HA binding, we then enriched solCD44s, solCD44sR41A and solCD44sR150/154A from culture supernatants by concentration (Figure 3c ).
HA binding competition assays were performed in which for soluble CD44 enriched supernatants competed with MM cells for binding to immobilized HA. Hyaluronic acid-coated 96-well plates were preincubated with the dierent solCD44s proteins (10 mg/ml) prior to incubation of the wells with MM cells. Following adhesion of the cells and subsequent washing, the remaining adherent proportion of cells was determined (Figure 4) . Unspeci®c binding was measured as cell adhesion to wells coated with BSA (Figure 4 ; HA+1F6 wt SN conc) indicating that the eects observed are dependent on soluble CD44. In summary, soluble CD44s is able to compete eciently with membrane-associated CD44 for HA binding.
Soluble CD44s inhibits hyaluronic acid-induced MM cell proliferation in vitro
There is evidence for a hyaluronic acid dependent increase in proliferation of MM cells. This increase of proliferation is inhibited completely by an anti-CD44 antibody which also blocks binding and adhesion of MM cells to hyaluronic acid (Ahrens et al., 2001 ). As shown above, the secreted form of CD44 inhibits MM cell adhesion to HA. We reasoned that binding of solCD44s to HA could also result in an inhibition of HA-induced proliferation. To test this hypothesis, MM cells were incubated for 48 h in HA coated and noncoated 96-well plates. For the parental cell line 1F6 and the controltransfected cells an increase in proliferation of 25 ± 30% above basal proliferation was observed when they were grown on HA-coated plates ( Figure 5 ; 1F6 wt+HA and 1F6 pcDNA3+HA). However, soluble CD44s-expressing cells did not display such a hyaluronic acid dependent increase in proliferation ( Figure 5 ; 1F6 solCD44s+HA). Signi®cantly, HA-induced proliferation was nevertheless observed in transfectants expressing solCD44sR41A or solCD44sR150/154A which do not bind HA ( Figure 5 ). We conclude that the soluble CD44s produced by MM cells binds to the immobilized HA and blocks cell surface CD44-mediated interactions with hyaluronic acid. This prevents the cell adhesion and induction of cell proliferation usually initiated by HA-CD44 interactions.
Expression of soluble CD44s results in suppression of melanoma tumor growth in vivo
The above mentioned experiments demonstrate that soluble CD44s interferes with cell surface CD44-mediated processes such as cell adhesion and proliferation of MM cells in vitro. To evaluate whether melanoma proliferation and tumor growth is also aected by soluble CD44s in vivo, we injected solCD44s-secreting MM cells subcutaneously into MF1 nu/nu mice ( Figure 6 ). As controls, nontransfected 1F6 cells and several mock-transfected 1F6 cell lines were also injected. The parental 1F6 cells (Figure 6 ; 1F6 wt) and mock-transfected cells (Figure 6 ; 1F6 pcDNA3) developed fast growing tumors within 10 ± 15 days after injection. Soluble CD44s-secreting transfectants in contrast showed a Identical results were also obtained after subcutaneous injection of the cell clones 1F6 pcDNA3 (a) and 1F6 solCD44 (a) (Figure 3b and data not shown). This dramatic growth inhibition is dependent on interactions of solCD44s with hyaluronic acid since a solCD44sR41A-secreting transfectant cell line ( Figure  7 ; 1F6 solCD44R41A (a)), where interactions between cell surface CD44 and HA are not disrupted, developed fast growing tumors similar to the parental cells (Figure 7; 1F6) . However, tumor growth of solCD44s-R41A secreting cells is delayed. This could be either caused by some residual HA binding capacity of the mutant protein or additional factors contributing to tumor growth delay in human melanoma e.g. apoptosis induction or disregulation of cell-cell contacts. Thus, the secretion of soluble CD44s eciently inhibits tumor cell proliferation in vivo, extending the results observed in vitro. This suppression of tumor development is critically dependent on the interaction of soluble CD44s with hyaluronic acid. These data suggest that solCD44 interferes with processes which lead to cell proliferation that are usually initiated by the interaction of cell surface CD44 with hyaluronic acid.
Discussion
In this study we describe shedding of the hyaluronic acid receptor CD44 from the surface of melanoma cells which is caused by proteolytic cleavage through metallo-and serine proteases. Enforced expression of secreted soluble CD44s completely abolished melanoma cell adhesion to immobilized HA and in addition inhibited the hyaluronic acid-induced proliferation of melanoma cells. In contrast, soluble CD44s with defective HA binding properties did not interfere with cell adhesion to hyaluronic acid and did not inhibit HA-induced proliferation. In vivo, a dramatic reduction in tumor growth was observed after subcutaneous injection of soluble CD44s-secreting cells into nu/nu mice. However, melanoma cells secreting soluble CD44s unable to bind to HA showed formation of primary tumors which was slightly retarded but still similar to the tumor development of non-transfected parental cells.
Proteolytic cleavage of membrane proteins is a common mechanism which regulates receptor expression on the cell surface (Bazil, 1995) . Shedding of adhesion molecules and involvement of proteases in the cleavage process has been previously reported for LSelectin , VCAM (Leca et al., 1995) and ICAM-1 (Champagne et al., 1998) . Metalloproteases have been associated with the cleavage of CD44 in TPA stimulated granulocytes (Bazil and Strominger, 1994) and a lung cancer cell line (Okamoto et al., 1999) . Using a variety of protease inhibitors we clearly identi®ed metalloproteases and serine proteases as being involved in the cleavage of CD44 in melanoma cells, whereas all other tested protease inhibitors only showed minor eects on CD44 shedding. To date, the proteolytic activity responsible for CD44 shedding has not been assigned to a speci®c protease.
The apparent molecular weight of shedded CD44 in MM cells is around 70 kDa, which is in agreement with the expected size for the extracellular, glycosylated part of CD44s. Variant epitopes were not detected in the soluble CD44 using a panel of dierent anti-variant CD44 mAb, which is also consistent with the shedded CD44 being the extracellular portion of CD44s. Although the exact cleavage site of membrane-bound CD44 has not been identi®ed, deletion of the membrane proximal domains of CD44 encoded by exons 15 and 16 does not abolish cleavage of CD44 (Okamoto et al., 1999) , which argues for a rather unde®ned cleavage site.
Increased tumor cell proliferation and metastasis formation has been associated with CD44-HA interactions (Bartolazzi et al., 1994 (Bartolazzi et al., , 1995 Sy et al., 1991 Sy et al., , 1992 . Furthermore, enhanced synthesis of hyaluronic acid by tumor cells has been proven to promote tumor growth (Kosaki et al., 1999) and metastasis Zhang et al., 1995) , and has also been observed in highly metastatic MM cell lines (Goebeler et al., 1996) . Moreover, an in¯uence of soluble CD44 on cell migration, tumor development and metastasis formation by melanoma cells has also been reported (Bartolazzi et al., 1994; Thomas et al., 1992; Zawadzki et al., 1998) , and most likely functions by interfering with cell surface CD44-HA interactions. Thus, soluble CD44 could have a major impact on melanoma tumor growth in vivo. The dramatic inhibition of primary tumor formation we observed for solCD44s-expressing MM cells is consistent with this notion. Tumor growth arrest was critically dependent on soluble CD44-HA interactions because soluble CD44s with impaired HA binding functions interfered with tumor development to a much smaller extent. The small eect of mutated soluble CD44s on tumor growth is consistent with our cell adhesion experiments in which the mutated soluble CD44 proteins displayed only small inhibiting eects on cell adhesion, perhaps due to residual HA binding capacity of the mutant proteins. Our data suggest that the HA binding function of CD44s plays a critical role in the growth of melanoma tumors, and that this function can be regulated by shedding of CD44s. In several experimental systems HA binding by soluble CD44 was found to be critical for the growth and metastasis inhibiting eects observed (Bartolazzi et al., 1994; Peterson et al., 2000; Sy et al., 1992; Yu et al., 1997) . We also found that an intact HA binding function of soluble CD44 is critical for competition with cell surface CD44. Competition of solCD44s with membrane-bound CD44 for HA binding sites could interfere with cellular processes usually initiated upon HA binding of cells. Here and in previous work (Ahrens et al., 2001) we have demonstrated that hyaluronic acid stimulates melanoma proliferation in a concentration-and CD44-dependent manner. This proliferation-inducing eect is blocked via release of soluble CD44 which still retains its HA binding capacity. This extends the eects of soluble CD44 that have been reported in the context of cell migration (Okamoto et al., 1999; Thomas et al., 1992) to cell proliferation of melanoma cells. Release of the growth factors bFGF and TGF-b1 are associated with the culture of MM cells on hyaluronic acid (Ahrens et al., 2001) . These results suggest an autocrine loop mechanism of proliferation induction via CD44-HA interactions and subsequent growth factor release.
In culture, soluble HA-binding CD44s was able to reduce proliferation of HA-treated melanoma cells to the proliferation levels observed in the absence of HA. However, in vivo, soluble HA-binding CD44s dramatically inhibited tumor growth. These data would suggest that MM tumor growth critically depends on HA-induced proliferation, perhaps through the autocrine stimulation we have observed in culture. Alternatively or in addition, solCD44s could have other functions. For example, it has been shown that increased cell death was found in a mammary carcinoma cell line as a result of solCD44v6-v10 secretion (Yu et al., 1997) , and solCD44s may act analogously in the case of MM.
The in¯uence of hyaluronic acid-CD44 interactions in the progression of gastric, colon, ovarian and breast cancer where poor prognosis is often associated with the expression of the CD44v6 epitope have not been addressed in detail. Variant CD44v6 has been shown to promote metastasis formation independent of interactions with hyaluronic acid (Sleeman et al., 1996) . In the case of melanoma the in¯uence of variant CD44v6 expression on the metastatic potential of the cells seems to be rather low (Simon et al., 1996) . Overexpression of cell surface CD44 in primary melanoma instead is often correlated with high risk of metastasis formation (Dietrich et al., 1997) , consistent with a critical role for CD44s in promoting tumor growth through ligating HA.
Elevated levels of soluble CD44 has been reported in the serum of patients with a variety of carcinomas (Guo et al., 1994; Lackner et al., 1998; Martin et al., 1997; Zeimet et al., 1997) . In contrast, no signi®cant elevation was found in sera from melanoma patients, although some primary and metastatic malignant melanoma patients showed high levels of solCD44s (Schaider et al., 1997) . Our data would suggest that high serum levels of solCD44s might be a positive prognostic factor for malignant melanoma patients. We therefore concur with the conclusion of Schaider et al. (1997) that malignant melanoma patients with high serum levels of solCD44s should be studied in more detail.
Finally, our results may have important clinical applications. We show that growth promoting signals in MM cells usually induced by direct interaction of cell surface CD44 with hyaluronic acid are eciently competed and inhibited by soluble CD44s. The loss of adhesive contacts between MM cells and hyaluronic acid results in a marked decrease in MM cell proliferation in vitro and tumor growth in vivo. Thus, disruption of receptor-ligand interactions by use of soluble forms of receptors may represent a possible target for antitumor therapy.
Materials and methods
Media and Reagents
MM cells were cultured in RPMI 1640 (Seromed, Eching, Germany) supplemented with penicillin G (50 U/ml, Gibco, Eggenstein, Germany), streptomycin (50 mg/ml, Gibco), 2 mM L-glutamine (Gibco) and 10% heat-inactivated fetal calf serum (PAA, Coelbe, Germany). Cultures of nontransformed melanocytes were maintained in selective melanocyte growth medium MGM (Promo Cell, Heidelberg, Germany). Rooster comb hyaluronic acid (Sigma, Deisenhofen, Germany) was used for HA-binding studies and proliferation assays. The CD44s ELISA-Kit (Bender Med Systems, Vienna, Austria) for the determination of solCD44 levels in MM cell culture supernatants was used according to the manufacturer's instructions. The following protease inhibitors were used: AEBSF in H 2 O (Boehringer Mannheim, Mannheim, Germany); 1,10-Phenanthroline in MeOH (Sigma); Pepstatin A in DMSO (Sigma) and Phosphoramidon in H 2 O (Sigma).
Cell lines and stable transfections
The MM cell line HT144 was obtained from the ATCC (Rockville, MD, USA), MV3 and 1F6 were a gift of Dr GP van Muijen (Dept. of Pathology, Nijmegen, The Netherlands), SB1 and SB3 were a gift of Dr CV Hamby (New York Medical College, Valhalla, NY, USA). Cultures of nontransformed melanocytes were established from human neonatal foreskin as described (Simon et al., 1996) . Purity (495%) of the melanocyte cultures was con®rmed by FACSstaining with the melanocyte-speci®c mAbs HMB-45 and S100. Melanocyte cultures between passages 2 and 5 (P2 to P5) were used for the experiments. Cultures were maintained at 378C in a humidi®ed 5% CO 2 atmosphere. To generate stable transfectants 5610 6 MM cells were resuspended in 500 ml medium containing 20 mg plasmid DNA. Cells were electroporated (950 mF, 250 V) in 0.4 mm electroporation cuvettes (BioRad, Muenchen, Germany) using a GenePulser (BioRad, Muenchen, Germany). After addition of 1 ml medium, cells were incubated for 10 min on ice. Cells were selected in medium containing 1 mg/ml G418 (Gibco). Resistant clones were picked 2 ± 3 weeks after application of the selection medium. Expression of the cDNAs was assessed by both Western blotting and CD44-ELISA analysis of cell culture supernatants.
Monoclonal antibodies
Following monoclonal antibodies were used: mlgG 1 control mAbs were obtained from Becton Dickinson (Heidelberg, Germany), anti-panCD44 (Hermes 3, mlgG 1 ) was a generous gift of Dr S Jalkanen (University of Turku, Finland), rat anti mouse CD44 mAb IM7 was purchased from Pharmingen (Pharmingen, Hamburg, Germany), HRP-conjugated goat anti-mouse lgG was obtained from DAKO (Hamburg, Germany).
Protease inhibitor studies
5610
3 melanoma cells per well were cultivated for 6 h on 96-well plates (Falcon, Heidelberg, Germany). After 6 h the level of CD44 shed into the cell culture supernatant was determined by CD44-ELISA (Bender Med Systems, Vienna, Austria). The protease inhibitors 1,10-Phenanthroline (2 mM), AEBSF (2 mM), Pepstatin A (1 mM) and Phosphoramidon (10 mM) were added in non toxic concentrations. Cells were then incubated for an additional 6 h at 378C. Cell culture supernatants were collected and solCD44 concentrations in the medium were measured by CD44-ELISA. As a control, nontreated 12 h supernatants were analysed. Data are depicted as mean values+s.d. of three independent experiments.
Cytotoxicity assay
Plasma membrane permeability of MM cells was assessed by Lactate dehydrogenase (LDH) release of the cells into the cell culture medium after 6 h of coculture with protease inhibitors. LDH was measured by a coupled enzymatic reaction using the Cobas Mira Plus system (Roche, Grenzach, Germany). Data are expressed as Units/Liter of mean values+s.d. of three independent experiments. solCD44 cDNA construction and site directed mutagenesis A truncated human CD44s cDNA encoding exons 1 ± 5, 15 and 16 (Screaton et al., 1992) , modi®ed by a 3' terminal TGA-stop codon, was cloned into the KpnI and EcoRV sites of the pcDNA3-Vector (Invitrogen, Groningen, The Netherlands). Mutated soluble CD44s expression constructs encoding solCD44sR41A and solCD44sR150A/R154A (Liao et al., 1995; Peach et al., 1993) were generated using the Quik Change TM site-directed mutagenesis kit (Stratagene, Heidelberg, Germany). In brief, 20 ng of the solCD44s expression vector were PCR ampli®ed (948C for 30 s, 558C for 1 min, 688C for 14 min; 16 cycles) with Pfu DNA polymerase using sense and antisense oligonucleotides containing the R41A or R150A/R154A mutations, respectively. Oligonucleotides used, were: R41A sense: 5'-CACGTGGAGAAAAATGGC-GCCTACAGCATCTCTCGG-3'; R41A antisense: 5'-CC-GAGAGATGCTGTAGGCGCCATTTTTCTCCACGTG-3'; R150A/R154A sense: 5'-CTATTGTCAACGCTGATGGCA-CCGCCTATGTCCAG-3'; R150A/R154A antisense: 5'-CT-GGACATAGGCGGTGCCATCAGCGTTGACAATAG -3'. The non-mutated parental supercoiled dsDNA was subsequently digested with 1 U DpnI After transformation of XL1-blue Supercompetent Cells, plasmid DNA was puri®ed and analysed by sequencing.
Enrichment of solCD44 from cell culture supernatants
Supernatants of transfectants grown for 48 h in expression medium containing 1% FCS were collected and concentrated using Centricon 100 columns with a molecular weight cut o 30 kDa (Amicon, Beverly, MA, USA). After dialysis against PBS w/o Mg 2+ /Ca 2+ , the solCD44 concentration was determined using a CD44-ELISA. For the subsequent HA binding assays, soluble CD44 was applied at a concentration of 10 mg/ml to HA coated plastic surfaces.
Western blot analysis
Two hundred and ®fty ng solCD44 were diluted in 1 ml lysis buer (PBS containing 0.5% NP-40 and 2 mM PMSF (Sigma)) and immunoprecipitated overnight at 48C with 5 mg/ml rat anti mouse CD44 mAb IM7 (Pharmingen, Hamburg, Germany) and 50 ml Protein A/G Sepharose beads (Calbiochem, Bad Soden, Germany) . After centrifugation at 14 000 r.p.m. for 4 min at 48C the immunoprecipitates were washed three times resolved in 26 non reducing Laemmlibuer, boiled for 5 min and separated by SDS ± PAGE (8% polyacrylamide gel). After centrifugation at 14 000 r.p.m. for 10 min, 25 mg of the total cell lysate were separated by SDS ± PAGE. Proteins were electrically transferred to PVDF membranes (Millipore, Eschborn, Germany). Detection of CD44 was performed using the anti human CD44 mAb Hermes 3 (5 mg/ml). Protein bands were visualized using the enhanced chemiluminescence (ECL) detection system (Amersham, Braunschweig, Germany).
Metabolic labeling and immunoprecipitation
5610
5 MM cells were cultured on 10 cm culture dishes for 24 h. Cells were then starved for 2 h in cRPMI (RPMI 1640 w/o methionine and cysteine; 10% dialyzed FCS; 2 mM Lglutamine, L-lysine and L-leucine). Afterwards CD44 was cleaved from the cell surface for 15 min with 1 ml 0.25% trypsin. Cells were replated and labeled for 48 h with 750 mCi L-35 S-methionine/cysteine (Amersham) per dish. Supernatants were collected and centrifuged (14 000 r.p.m., 3 min, 48C).
solCD44-HA interactions and MM tumor progression T Ahrens et al Cells were lysed in 1 ml RIPA-buer and also centrifuged. Cell lysates and respective supernatants were precleared over night with 100 ml Protein A/G Sepharose beads. CD44 was then immunoprecipitated for 2 h at 48C with anti-panCD44 mAb Hermes 3 (5 mg/ml) and Protein A/G Sepharose beads.
Immunoprecipitates were washed four times with RIPAbuer and after boiling the samples at 908C for 5 min the immunoprecipitated proteins were separated by SDS ± PAGE. After incubation in PPO (20% w/v in DMSO) the gel was dried and analysed by autoradiography.
Cell adhesion assays
Hyaluronic acid (1 mg/ml in 50 mM NaHCO 3 -buer, pH 9.6) was coated overnight on 96-well¯at bottom plates (Greiner, Frickenhausen, Germany) . To avoid unspeci®c binding, plates were subsequently coated with 1% (w/v) heat denatured BSA (Sigma) in PBS for 1 h at 378C and washed again with PBS. Ten mg/ml of solCD44, solCD44sR41A and solCD44sR150A/R154A of dierent MM cell lines were then added to the 96-well plates for 2 h at 48C. 5610 4 [ 3 H]thymidine (Amersham) prelabeled cells were seeded per well and plates were incubated for 45 min at 48C. After rinsing the wells three times with PBS, remaining adherent cells were harvested and counted using a liquid scintillation b-counter (Top-Count, Canberra Packard, Dreieich, Germany). As a control, adhesion to 1% (w/v) BSA coated wells was measured. The percentage of cell adhesion was determined as ratio of counts/min of remaining adherent cells to counts/min of the 5610 4 initially applied cells.
Proliferation assays
Ninety-six-well¯at bottom plates (Falcon) were coated overnight at 48C with 100 ml heat inactivated (20 min at 1008C) hyaluronic acid (1.0 mg/ml in 50 mM NaHCO 3 -buer, pH 9.6). 
